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BACKGROUND AND OBJECTIVES
Mycobacterium tuberculosis, which resides inside 
macrophages, has always been recognized as one 
of the most “successful” pathogens. Standard treat-
ments have already been used for decades and, 
therefore, resistances to the first-line medicines are 
increasing. Additionally, poor patient compliance with 
stringent therapies is often pointed out as a major 
reason leading to treatment failure.
Antimicrobial peptides (AMPs), a promising new 
class of broad spectrum antibiotics, are less prone 
to result in pathogen resistances due to their tar-
get (cellular membranes) and rapid action. In our 
laboratory we search for AMPs with potent activity 
against mycobacteria and try to develop efficient 
delivery systems based on self-assembled colloidal 
nanocarriers. Additionally, this systems are expected 
to reduce peptide toxicity and enhance selective 
uptake on infected cells. Finally, the use of encap-
sulated drugs in mycobacterial therapy may help 
reducing drug administration schedules which would 
ultimately improve patient compliance.
WORK PLAN
1. Optimization of therapeutic formulations for 
AMPs controlled delivery. 
2. In vitro and in vivo delivery of AMPs to infected 
macrophages; Analysis of mechanisms of ther-
apeutic action and potential side effects. 
3. Study binding, internalization mechanisms and 
intracellular fate of the nanocarriers (University 
of Oxford).
4. In vivo biodistribution of the nanocarrier (Uni-
versity of Groningen). 
5. Study the global pharmacoeconomic impact 
of AMPs as new therapeutic agents to fight 
tuberculosis. 
RESULTS
We have used encapsulated AMPs (Fig. 1) to tackle 
an infection promoted by M. avium in mouse mac-
rophages in vitro. During 7 days the peptide has 
killed more than 99% of initial bacterial burden. The 
bactericidal effect has already been confirmed using 
infected mice in vivo, by applying the therapeutic for-
mulation via the pulmonary route (Fig. 2). Currently, 
we are moving for more potent mycobacteria, such 
as M. tuberculosis, which shows identical suscepti-
bility to the antimicrobial formulation.
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FIGURE 1
Schematic representation of the peptide nanocarrier.
FIGURE 2
Intratracheal drug delivery using a MicroSprayer® aerosolizer in mice. 
